Interleukin 15 levels in serum may predict a severe disease course in patients with early arthritis
AuthorGonzález-Alvaro, Isidoro; Ortíz, Ana María; Álvaro-Gracia, José María; Castañeda Sanz, Santos; Díaz-Sánchez, Belén; Carvajal, Inmaculada; García Vadillo, Jesús Alberto; Humbría, Alicia; López-Bote, Juan Pedro; Patiño, Esther; Tomero, Eva G.; Vicente, Esther; Sabando, Pedro; García de Vicuña Pinedo, María del Rosario
EntityUAM. Departamento de Medicina
PublisherPublic Library of Science
10.1371/journal.pone.0029492Plos One 6.12 (2011): e29492
Funded byThe work of Belen Díaz-Sánchez was supported by the RETICS Programme (Programa de Redes Temáticas de Investigación Colaborativa [Colaborative Research Thematic Network Programme]; RD08/0075 - RIER [Red de Inflamación y Enfermedades Reumáticas; Inflammation and Rheumatic Diseases Network]) from the Instituto de Salud Carlos III, Spain (URL: www.isciii.es) within the VI National Plan for I+D+I 2008–2011 (FEDER). The work of Isidoro González-Álvaro was in part supported by a grant for the Intensification of the Research Tasks in the National Health Care System from Instituto de Salud Carlos III, Spain. The consumables for measurements and data analysis were supported by a Fondo de Investigación Sanitaria grant (08/0754) from the Instituto de Salud Carlos III
SubjectsArthritis; Autoantibodies; Age of Onset; Antirheumatic Agents; Interleukin-15; Risk Factors; Medicina
Rights© 2011 González-Álvaro et al.
Esta obra está bajo una Licencia Creative Commons Atribución 4.0 Internacional.
Background: Interleukin-15 (IL-15) is thought to be involved in the physiopathological mechanisms of RA and it can be detected in the serum and the synovial fluid of inflamed joints in patients with RA but not in patients with osteoarthritis or other inflammatory joint diseases. Therefore, the objective of this work is to analyse whether serum IL-15 (sIL-15) levels serve as a biomarker of disease severity in patients with early arthritis (EA). Methodology and Results: Data from 190 patients in an EA register were analysed (77.2% female; median age 53 years; 6-month median disease duration at entry). Clinical and treatment information was recorded systematically, especially the prescription of disease modifying anti-rheumatic drugs. Two multivariate longitudinal analyses were performed with different dependent variables: 1) DAS28 and 2) a variable reflecting intensive treatment. Both included sIL-15 as predictive variable and other variables associated with disease severity, including rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibodies (ACPA). Of the 171 patients (638 visits analysed) completing the follow-up, 71% suffered rheumatoid arthritis and 29% were considered as undifferentiated arthritis. Elevated sIL-15 was detected in 29% of this population and this biomarker did not overlap extensively with RF or ACPA. High sIL-15 levels (β Coefficient [95% confidence interval]: 0.12 [0.06-0.18]; p&0.001) or ACPA (0.34 [0.01-0.67]; p = 0.044) were significantly and independently associated with a higher DAS28 during follow-up, after adjusting for confounding variables such as gender, age and treatment. In addition, those patients with elevated sIL-15 had a significantly higher risk of receiving intensive treatment (RR 1.78, 95% confidence interval 1.18-2.7; p = 0.007). Conclusions: Patients with EA displaying high baseline sIL-15 suffered a more severe disease and received more intensive treatment. Thus, sIL-15 may be a biomarker for patients that are candidates for early and more intensive treatment
Google Scholar:González-Alvaro, Isidoro - Ortíz, Ana María - Álvaro-Gracia, José María - Castañeda Sanz, Santos - Díaz-Sánchez, Belén - Carvajal, Inmaculada - García Vadillo, Jesús Alberto - Humbría, Alicia - López-Bote, Juan Pedro - Patiño, Esther - Tomero, Eva G. - Vicente, Esther - Sabando, Pedro - García de Vicuña Pinedo, María del Rosario
This item appears in the following Collection(s)
Showing items related by title, author, creator and subject.
Utility of circulating serum miRNA profiles to evaluate the potential risk and severity of immune-mediated inflammatory disorders Martínez-Hernández, Rebeca; Fuente, Hortensia de la; Lamana, Amalia; Sampedro-Núñez, Miguel; Ramos-Levi, Ana; Serrano-Somavilla, Ana; García de Vicuña Pinedo, María del Rosario; Ortiz, Ana M.; Daudén Tello, Esteban; Llamas-Velasco, Mar; Chicharro, Pablo; Rodríguez-Jiménez, Pedro; Sanz-García, Ancor; Sánchez Madrid, Francisco; González-Álvaro, Isidoro; Marazuela Azpiroz, Mónica
Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial
Experience with the use of Rituximab for the treatment of rheumatoid arthritis in a tertiary Hospital in Spain: RITAR study